Navigation Links
VIVUS Reports First Quarter 2009 Financial Results and Highlights
Date:5/11/2009

MOUNTAIN VIEW, Calif., May 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its highlights and financial results for the first quarter ended March 31, 2009.

First Quarter 2009 Highlights:

  • Issuance of Key European Patent for Qnexa - In January 2009, we announced that the European Patent Office had granted a patent for Qnexa. The European patent, No. 1,187,603, broadly covers Qnexa and its use as a weight loss treatment and extends the intellectual property protection of Qnexa beyond the already issued patents in the United States and abroad.

  • Qnexa Treatment Resulted in Improved Glucose Control in Obese Non-Diabetic Subjects - In January 2009, we announced additional results from the EQUATE study (OB-301) which found that EQUATE study subjects treated with Qnexa had a significant reduction in HbA1c compared to the increase in HbA1c observed in the placebo treated subjects. The EQUATE study was designed as a weight loss trial; however, additional analysis of the results showed that Qnexa treatment can have a positive impact on the blood sugar levels of non-diabetics.

  • Senior Management Promotions - In January 2009, we announced that Peter Tam had been promoted to chief operating officer (COO). In his capacity as COO, Mr. Tam will continue to have overall responsibility for business development, clinical and preclinical development, regulatory affairs and chemistry, manufacturing and controls. In addition, Charles Bowden, M.D., was promoted to senior director, clinical development. Dr. Bowden has assumed r
    '/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Wheaton, Illinois (PRWEB) May 04, 2015 ... treatment options for patients with arm and hand ... rehabilitation exoskeleton at its Oakbrook Terrace network site. ... foundation, the Armeo®Spring is a highly-regarded treatment option ... In acquiring the Armeo®Spring, Marianjoy becomes one of ...
(Date:5/1/2015)... 01, 2015 OncoTAb, Inc., ... spin-out company, announced that Pinku Mukherjee, Ph.D. has received ... Board of Governors’ highest faculty honor. Mukherjee received the ... , for her innovative research and development of cancer ... represents a crowning moment in my scientific career,” said ...
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... A new report by  visiongain ... reach $22.4bn in 2019. That revenue forecast and others ... Prospects 2015-2025 ,  published in March 2015. ... provide forecasts and qualitative analyses of the antithrombotic drugs ... in London, UK . It produces ...
Breaking Biology Technology:Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... Participate at the "Facing ... JERUSALEM, Israel, May 6 Oramed,Pharmaceuticals, Inc. (OTCBB: ... for the first annual Presidential conference, "Facing,Tomorrow," as one ... of Israel. The monumental event is being held to ...
... May 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today ... on Wednesday, May 7, 2008., The Company has ... results on May 7, 2008, at 11:00 AM EDT. ... at least,five minutes prior to the call. A replay ...
... (NYSE: BSX ) announced today that a ... its ruling in an,arbitration between the Company and ... to the 2005 settlement agreement between,the companies, alleged ... U.S. and European patents held by Medinol. The,arbitrators ...
Cached Biology Technology:Israel's Prestigious President's Conference to Feature Oramed Pharmaceuticals' Revolutionary Oral Insulin Capsule 2NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... of interesting ?and potentially life-saving ?biological molecules. But tracking ... can be time-consuming, expensive and unreliable. , Now Salk ... of the rainforest and into the lab. Their findings ... journal Nature. , Stéphane Richard, Joseph Noel and Tomohisa ...
... reports ?one from Louisiana, one from Japan and ... pointing to involvement of endocannabinoids as a novel ... applications in eating, disease treatment and social behavior. ... The team from Tulane and Louisiana State Universities, ...
... to one another through the routine exchange of electrical ... the higher regions of the brain - regions that ... dialogue - apparently lose their ability to communicate effectively, ... in the journal Science, a team of researchers led ...
Cached Biology News:Stem cell training program to make its Stanford debut 2Stem cell training program to make its Stanford debut 3Endocannabinoids ?the brain's cannabis ?demonstrate novel modes of action to stress 2Frog peptides block HIV in lab study 2Frog peptides block HIV in lab study 3
... EKMax™ is a recombinant preparation of ... EKMax™ Enterokinase is expressed and isolated from ... highly purified enzyme preparation (2). It recognizes ... bond after the lysine residue. The enzyme ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
...
...
Biology Products: